April 17, 2018 / 8:07 PM / 10 days ago

BRIEF-Catabasis Pharma Aligns Resources To Focus On Lead Program Edasalonexent

April 17 (Reuters) - Catabasis Pharmaceuticals Inc:

* CATABASIS PHARMACEUTICALS ALIGNS RESOURCES TO FOCUS ON LEAD PROGRAM EDASALONEXENT FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

* CATABASIS PHARMACEUTICALS INC - STRATEGIC CORPORATE RESTRUCTURING SUPPORTS GOAL OF ADVANCING EDASALONEXENT TOWARDS POTENTIAL REGISTRATION

* CATABASIS PHARMACEUTICALS INC - RESTRUCTURING WILL REDUCE COMPANY’S WORKFORCE BY APPROXIMATELY 42%

* CATABASIS PHARMACEUTICALS INC - ESTIMATES ANNUALIZED SAVINGS OF APPROXIMATELY $3.3 MILLION IN PERSONNEL-RELATED COSTS

* CATABASIS PHARMACEUTICALS INC - ESTIMATED ONE-TIME SEVERANCE AND RELATED COSTS OF APPROXIMATELY $1.0 MILLION IN Q2 OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below